MA50245A - Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 - Google Patents
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2Info
- Publication number
- MA50245A MA50245A MA050245A MA50245A MA50245A MA 50245 A MA50245 A MA 50245A MA 050245 A MA050245 A MA 050245A MA 50245 A MA50245 A MA 50245A MA 50245 A MA50245 A MA 50245A
- Authority
- MA
- Morocco
- Prior art keywords
- octahydrocyclopenta
- shp2
- pyrrole
- allosteric inhibitors
- allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762556713P | 2017-09-11 | 2017-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50245A true MA50245A (fr) | 2020-07-22 |
Family
ID=63794616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050245A MA50245A (fr) | 2017-09-11 | 2018-09-11 | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10435389B2 (fr) |
EP (1) | EP3681879A1 (fr) |
JP (2) | JP7447002B2 (fr) |
CN (1) | CN111201223A (fr) |
CA (1) | CA3074304A1 (fr) |
MA (1) | MA50245A (fr) |
TW (1) | TW201912639A (fr) |
WO (1) | WO2019051469A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017210134A1 (fr) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Inhibiteurs hétérocycliques de ptpn11 |
EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
EP3630770A1 (fr) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2 |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
CA3094690A1 (fr) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Inhibiteurs de la phosphatase shp2 et leurs procedes d'utilisation |
EP3787627A4 (fr) | 2018-05-02 | 2021-12-01 | Navire Pharma, Inc. | Inhibiteurs hétérocycliques substitués de ptpn11 |
AU2019319971A1 (en) | 2018-08-10 | 2021-03-25 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
MX2021003158A (es) | 2018-09-18 | 2021-07-16 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2. |
WO2020072656A1 (fr) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
KR20210146288A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로사이클릴 화합물 및 이의 용도 |
JP2022524759A (ja) | 2019-03-07 | 2022-05-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 |
AU2020251841A1 (en) | 2019-04-02 | 2021-10-07 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
WO2020210384A1 (fr) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Dérivés de pyrimidinone utilisés en tant qu'antagonistes de shp2 |
EP4034539A1 (fr) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2, procédés de production et d'utilisation associés |
JP2022553857A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
WO2021108683A1 (fr) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ras抑制劑 |
AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
WO2022235864A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras |
CN114716448B (zh) * | 2021-05-13 | 2024-01-30 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0647450A1 (fr) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Prodrogues améliorées pour activation médiée par enzyme |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
ATE267191T1 (de) * | 1996-10-25 | 2004-06-15 | Daiichi Seiyaku Co | Tricyclische aminderivate |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
WO1999063932A2 (fr) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Agents de liaison multiple, modulant le transporteur de 5-ht |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
US20040089753A1 (en) | 2000-06-28 | 2004-05-13 | Holland Simon Joseph | Wet milling process |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
RU2312861C2 (ru) | 2002-03-05 | 2007-12-20 | Мерк Фросст Кэнада Лтд. | Ингибиторы катепсин-цистеинпротеазы |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
PT1789390E (pt) | 2004-09-02 | 2012-02-08 | Genentech Inc | Inibidores de piridilo da sinalização de hedgehog |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
MX338504B (es) | 2007-09-12 | 2016-04-20 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
UY32261A (es) * | 2008-11-26 | 2010-06-30 | Abbott Lab | Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio |
FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
EP2447263A1 (fr) | 2010-09-27 | 2012-05-02 | Bioprojet | Dérivés de benzazole en tant que ligands du récepteur H4 |
KR101271224B1 (ko) * | 2011-07-05 | 2013-06-10 | 한국과학기술연구원 | 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법 |
JP2014525452A (ja) * | 2011-08-29 | 2014-09-29 | ピーティーシー セラピューティクス, インコーポレイテッド | 抗菌化合物および使用方法 |
TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
WO2016203404A1 (fr) | 2015-06-19 | 2016-12-22 | Novartis Ag | Composés et compositions pour inhiber l'activité de shp2 |
EP3310771B1 (fr) | 2015-06-19 | 2020-07-22 | Novartis AG | Composés et compositions pour l'inhibition de l'activité de shp2 |
WO2017156397A1 (fr) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Inhibiteurs hétérocycliques de ptpn11 |
CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
CA3026784A1 (fr) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Derives de pyrazine heterocycliques utiles en tant qu'inhibiteurs de shp2 |
MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
MX2019000548A (es) | 2016-07-12 | 2019-10-30 | Revolution Medicines Inc | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2. |
EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
RU2769132C2 (ru) | 2017-01-10 | 2022-03-28 | Новартис Аг | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 |
CA3051054A1 (fr) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Composes de pyridine utilises en tant qu'inhibiteurs allosteriques de shp2 |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
EP3630770A1 (fr) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2 |
-
2018
- 2018-09-11 WO PCT/US2018/050397 patent/WO2019051469A1/fr unknown
- 2018-09-11 MA MA050245A patent/MA50245A/fr unknown
- 2018-09-11 EP EP18783183.9A patent/EP3681879A1/fr active Pending
- 2018-09-11 US US16/127,772 patent/US10435389B2/en active Active
- 2018-09-11 CA CA3074304A patent/CA3074304A1/fr active Pending
- 2018-09-11 JP JP2020536724A patent/JP7447002B2/ja active Active
- 2018-09-11 CN CN201880058453.6A patent/CN111201223A/zh active Pending
- 2018-09-11 TW TW107131932A patent/TW201912639A/zh unknown
-
2024
- 2024-02-28 JP JP2024028064A patent/JP2024059874A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020535218A (ja) | 2020-12-03 |
WO2019051469A1 (fr) | 2019-03-14 |
CA3074304A1 (fr) | 2019-03-14 |
TW201912639A (zh) | 2019-04-01 |
JP2024059874A (ja) | 2024-05-01 |
EP3681879A1 (fr) | 2020-07-22 |
US20190077792A1 (en) | 2019-03-14 |
US10435389B2 (en) | 2019-10-08 |
JP7447002B2 (ja) | 2024-03-11 |
CN111201223A (zh) | 2020-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50245A (fr) | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 | |
MA54543A (fr) | Inhibiteurs de kif18a | |
MA54550A (fr) | Inhibiteurs de kif18a | |
DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
MA52413A (fr) | Inhibiteurs de cd73 | |
IL268030B (en) | Bicyclics as allosteric shp2 inhibitors | |
IL275353A (en) | Amide-converted indole compounds for use as TLR inhibitors | |
IL275356A (en) | Modified indole compounds for use as TLR inhibitors | |
MA52812A (fr) | Inhibiteurs de sarm1 | |
IL275504A (en) | Indole amino compounds for use as TLR inhibitors | |
MA53287A (fr) | Inhibiteurs de prmt5 | |
IL276813A (en) | Arginase inhibitors | |
DK3681884T3 (da) | Rad51-inhibitorer | |
MA53491A (fr) | Inhibiteurs de sarcomes cardiaques | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3774817T3 (da) | Bcl6-hæmmere | |
DK3625224T3 (da) | N-substituerede indolderivater | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
MA55909A (fr) | Inhibiteurs de cdk | |
IL275195A (en) | History of pyrrole as ACC inhibitors | |
DK3795167T3 (da) | Pd-1-peptidinhibitorer | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
MA52809A (fr) | Inhibiteurs de sarm1 | |
MA52813A (fr) | Inhibiteurs de sarm1 |